The effects of gemfibrozil upon the hypercoagulable state in dyslipidaemic patients with chronic renal failure

Nephrology Dialysis Transplantation

Volumn 11, Issue 11, 1996, Pages 2223-2228

  Irish, A B ^a   Thompson, C H ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Chronic renal failure; Fibrinogen; Gemfibrozil; Insulin; Interleukin 6; Lipids; Lipoprotein (a); Prothrombin fragment F1 + 2

Indexed keywords

FIBRINOGEN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; TRIACYLGLYCEROL;

ACUTE PHASE RESPONSE; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; PRIORITY JOURNAL; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029987545     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.ndt.a027140     Document Type: Article

References (42)

1. Hamsten A. The hemostatic system and coronary heart disease. Thromb Res 1993; 70: 1-38
2. Meade TW, Mellows S, Brozovie M et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537
3. Miller GJ, Martin JC, Mitropoulos KA et al. Plasma factor VII is activated by postprandial triglyceridaemia, irrespective of dietary fat composition. Atherosclerosis 1991; 86: 163-171
4. Rapaport SI, Rao LVJ. The tissue factor pathway: how it has become a 'Prima Ballerina'. Thromb Haemost 1995; 74(1): 7-17
5. Mitropoulos KA, Esnouf MP. The prothrombin activation peptide regulates synthesis of the vitamin K-dependent proteins in the rabbit. Thromb Res 1990; 57: 541-545
6. Rosenberg RD, Bauer KA. Prothrombin activation fragment assay. Clin Chem 1993; 39(4): 559-560
7. Tomura S, Nakamura Y, Deguchi F, Ando R. Chida Y, Marumo F. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment. Thromb Res 1991; 64: 81-90
8. Kario K, Matsuo T, Yamada T, Nakao K, Shimano C, Matsuo M. Factor VII hyperactivity in chronic dialysis patients. Thromb Rex 1992; 67: 105-113
9. Kario K, Matsuo T, Matsuo M et al. Marked increase of activated factor VII in uremic patients. Thromb Haemost 1995; 73(5): 763-767
10. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079
11. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: Its role in thrombotic disease. Thromb Haemost 1995; 74(1): 71-76
12. Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis 1992; 95: 105-117
13. Reaven GM, Laws A. Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease. Diabetologia 1994; 37: 948-952
14. Gault MH, Longrich LL, Purchase L, Harnett J, Breckenridge C. Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. Nephron 1995; 70: 150-170
15. Irish AB, Simons LA, Savdie E, Hayes JM. Simons J. Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation. Aust NZ J Med 1992; 22: 243-248
16. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in haemodialysis patients. Circulation 1992; 86: 475-482
17. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA. Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 1994; 5: 354-357
18. Kronenberg F, Kathrein H, König P et al. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease, Arterioscler Thromb 1994; 14: 1405-1411
19. Etingen O, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. J Biol Chem 1991; 266: 2459-2465
20. Dang CV, Bell WR, Shuman M. The normal and morbid biology of fibrinogen. Am J Med 1989; 87: 567-576
21. Koenig W, Ernst E. Fibrinogen and atherothrombogenesis. Curr Opin Lipidol 1993; 4(6): 471-476
22. Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med 1987; 83 [Suppl 5B]: 9-20
23. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245
24. Chan MK. Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis; the role of postheparin lipases in the metabolism of high-density lipoprotein subfractions. Metabolism 1989; 38(10): 939-945
25. Wilkes HC, Meade TW, Barzegar S et al. Gemfibrozil reduces plasma prothrombin fragment F1+2 concentration, a marker of coagulability in patients with coronary heart disease. Thromb Haemost 1992; 67(5): 503-506
26. Andersen P, Smith P, Seljeflot I, Brataker S, Arnesen H. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemost 1990; 63(2): 174-177
27. Avellone G, Di Garbo V, Cordova R et al. Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridaemia. Blood Coag Fibrinolysis 1995; 6: 543-548
28. UK Prospective Diabetes Study Group. UK prospective diabetes study (UKPDS) XI: biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabetic Med 1994; 11: 534-544
29. Pasternack A, Vänttinen T, Solakivi T, Kuusi T, Korte T. Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure. Clin Nephrol 1987; 27(4): 163-168
30. Elisaf MS, Dardamanis MA, Papagalanis ND, Siamopoulos KC. Lipid abnormalities in chronic uremic patients. Scand J Urol Nephrol 1993; 27: 101-108
31. Appel GB, Jacobs C, Markell MS, Iaina A, Weintraub M. How should the lipid abnormalities of dialysis patients be treated? Semin Dial 1995; 8(1): 15-22
32. Tan K, Betteridge DJ, Marmot MG, Talmud P, Humphries SE, Yudkin JS. Hypertriglyceridaemia and vascular risk. Lancet 1993; 341: 781-786
33. Durrington PN. How HDL protects against atheroma. Lancet 1993; 342: 1315-1316
34. Hahn R, Oette K, Mondorf H, Finke K, Sieberth HG. Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis 1983; 48: 279-288
35. Key NS. Scratching the surface: endothelium as a regulator of thrombosis, fibrinolysis and inflammation. J Lab Clin Med 1992; 120(2): 184-186
36. Mannucci PM, Giangrande PLF. Detection of the prethrombotic state due to procoagulant imbalance, Eur J Haematol 1992; 48: 65-69
37. ten Cate H, Bauer KA, Levi M et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-1212
38. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A. Effect of three fibric acid derivatives and of two HMG-coA reductase inhibitors on plasma fibrinogen levels in patients with primary hypercholesterolaemia. Thromb Haemost 1993; 70: 241-243
39. Koenig W, Hoffmeister HCA, Nehmer C et al. How do flbrates lower fibrinogen? The possible role of interleukin-6 suppression. Blood Coag Fibrinolysis 1994; 5 [Suppl 2]: 16-17
40. De Maat MPM, Knipscheer HC, Kastelein JJP, Kluft K. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia. Blood Coag Fibrinolysis 1994; 5 [Suppl 2]: 17
41. Zwaginga JJ, Koomans HA, Sixma LL, Rabelink TJ. Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions. J Clin Invest 1994; 93: 204-211
42. Uterman G. The mysteries of lipoprotein(a). Science 1989; 246: 904